Register for our free email digests:
Latest From Chiesi Farmaceutici SPA
GSK's triple COPD combo needs Phase III trial using comparators with same active ingredients and applying factorial design, BI contends in citizen petition to US FDA.
Chiesi's triple combination therapy for COPD, Trimbow, has secured its first approval globally after winning a positive recommendation from the CHMP for its use in Europe – but analysts expect a respiratory partner will be required to launch the product.
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
- Therapeutic Areas
- Neurology, Nervous System
- NeuralStem BioPharmaceuticals Ltd.
- North America
- Parent & Subsidiaries
- Neuralstem Inc.
- Senior Management
Richard Daly, Pres. & CEO
Jonathan Lloyd Jones, CFO
Karl Johe, PhD, CSO
Thomas G Hazel, PhD, SVP, Research
- Contact Info
Phone: (301) 366-4960
20271 Goldenrod Lane
Germantown, MD 20876
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.